Search

Your search keyword '"Watson-Jones, D"' showing total 228 results
Start Over Author "Watson-Jones, D"
228 results on '"Watson-Jones, D"'

1. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

Author

Mooney, T, Conteh, L, Bangura, MS, Bangura, MA, Jalloh, H, Kamara, I, Kamara, M, Koroma, S, Sesay, M, Sesay, MT, Deen, AT, Kamara, A, Kamara, EL, Kamara, SLM, Koroma, AH, Mansaray, IS, Massaquoi, MJ, Nabie, A, Kowuor, D, Njie, Y, Odeny, L, Sheku, M, Jalloh, AB, Sow, A, Swaray, E, Mansaray, F, Sessie, T, Sunders, J-HC, Turay, SI-S, Weekes, J, Pessima, M, Wurie, A, Conteh, M, Jalloh, MI, Kamara, PBD, Kanneh, DP, Kanneh, M, Komeh, I, Koroma, M, Kuyateh, M, Mansaray, FF, Leigh, B, Watson-Jones, D, Samai, M, Deen, GF, Sesay, T, Piot, P, Greenwood, B, Lees, S, Larson, H, Afolabi, M, Ishola, D, Baiden, F, Faye, F, Tindanbil, D, Kamara, MM, Swaray, IB, Bangura, A, Kamara, AB, Morovia, FE, Kallon, JA, Murray, M, Sesay, F, Suma, F, Sesay, IG, Choi, EM, Manno, D, Foster, J, Rwezaula, R, Akhigbe, I, Adetola, H, Kamara, B, Lowe, B, Lawal, B, Kohn, B, Tuda, GO, Koroma, F, Bangura, G, Kroma, MT, Fofanah, L, Pessima, A, Rogers, M, Sheriff, O, Fangawa, J, Foday, S, Jabbie, I, Mansaray, HA, Sesay, K, Jakema, HB, Sheku, MF, Jalloh, KFN, Kabba, M, Kanjie, F, Kanu, AP, Kassa-Koroma, G, Jusu, M, Koroma, B, Borboh, P, Kallon, A, van Roey, K, Conteh, P, Samura, M, Gandie, V, Marrah, M, Kalokoh, J, Bangura, MI, Connor, N, Saidu, S, Turay, AS, Lahai, A, Johnson, CL, Kogba, DB, Vincent, W, Bangura, M, Tengbeh, A, Bangura, K, Kabia, R, Nyakoi, AM, Lee, S, Nyaberi, D, Ndingi, S, Nyallay, L, Bangura, AR, Idriss, B, Sillah, M, Mackay, W, Murray, T, Edem-Hotah, J, Fatorma, T, Bangura, S, Bonnie, E, Sannoh, M, Malcolm, S, Brown, J, Snowden, E, Howard, K, Ojugo, A, Massin-Shepherd, C, BEAVOGUI, AH, KEITA, CM, CAMARA, OK, GUILAVOGUI, JPY, BAH, H, SAMOURA, MA, MUAMBA, D, SEMAKUBA, B, CAMARA, AK, KABA, AS, BERERD-CAMARA, M, YARADOUNO, M, DECHENAUD, M, CAMARA, MT, TAMBALOU, J, HABA, M, DIALLO, SD, THEA, A, DOUMBOUYA, N, FOFANA, ML, BEAVOGUI, M, CAMARA, AA, BEAVOGUI, JT, DIOUF, W, AUGIER, A, BARTE DE SAINTE FARE, E, SIVAHERA MUYISA, B, SANI, S, VATRINET, R, HAMZE, B, LACARRA, B, D’ORTENZIO, E, ALE, B, BETARD, C, RICHERT, L, OULAI, D, KANTE, M, SOUTTHIPHONG, A-A, SCHWIMMER, C, THIÉBAUT, R, OTTAVI, A, COUFFIN-CADIERGUES, S, ESPEROU, H, Chai, SP, Buth, W, Offergeld, K, Menten, A, Hammoud, N, De Ridder, S, Sellecchia, R, in ’t Veld, R, Fogap, N, Anumendem, D, Stapleton, H, Reijns, T, Haydon, J, Roza, L, Sawyer, B, Hoda, S, Yee, J, De Cnodder, T, Hubin, E, Telen, L, Desai, J, Bennet, M, Pawlowski, M, van Gils, N, Boeykens, N, Kwasniak, A, Ligthart, M, Van Roey, G, Fernandez, E, Gaddah, A, van Dijck, W, Jingshuang, S, Randrasana, S, Artis, C, Akinbinu, A, Poretti, A, Van Ballaert, S, Harris, M, Van Looveren, M, Brandt, P, Robinson, C, Bockstal, V, McLean, C, Versteege, I, Ferrault, C, Kaminski, A, Vergauwen, H, Kerama, CI, Forcheh, CA, DiMondi, CV, Stewart, L, Meurer, J, Beounitis, A, Peeters, J, Su, C, Keshinro, B, Delport, C, Sharkie, E, Zhang, J, Du, C, Hu, K, Strydom, A, Bezem-Aviv, I, Wachnicka, A, Kumar, P, Cheng, S, Kang, K, Choi, Edward Man-Lik, Lacarra, Boris, Afolabi, Muhammed O, Ale, Boni Maxime, Baiden, Frank, Bétard, Christine, Foster, Julie, Hamzé, Benjamin, Schwimmer, Christine, Manno, Daniela, D’Ortenzio, Eric, Ishola, David, Keita, Cheick Mohamed, Keshinro, Babajide, Njie, Yusupha, van Dijck, Wim, Gaddah, Auguste, Anumendem, Dickson, Lowe, Brett, Vatrinet, Renaud, Lawal, Bolarinde Joseph, Otieno, Godfrey T, Samai, Mohamed, Deen, Gibrilla Fadlu, Swaray, Ibrahim Bob, Kamara, Abu Bakarr, Kamara, Michael Morlai, Diagne, Mame Aminata, Kowuor, Dickens, McLean, Chelsea, Leigh, Bailah, Beavogui, Abdoul Habib, Leyssen, Maarten, Luhn, Kerstin, Robinson, Cynthia, Douoguih, Macaya, Greenwood, Brian, Thiébaut, Rodolphe, and Watson-Jones, Deborah

Published
2023
Full Text
View/download PDF

2. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

Author

Kargbo, M, Bockarie, E, James, N L, Kabbah, A, Kamara, A, Koroma, K H, Langley, S O, William, N, Kessebeh, R, Mooney, T, Conteh, L, Smout, E, Allieu, K, Bangura, K, Bangura, M S, Bangura, M A, Jalloh, H, Jalloh, A B, Kamara, I, Kamara, M, Konteh, A, Koroma, S, Marrah, C, Sesay, M, Sesay, M T, Deen, A T, Jalloh, A, Kaimbay, R M, Kain, D, Kamara, E L, Kamara, M P, Kamara, O J, Kamara, S L M, Kanneh, M, Koroma, A H, Lahai, D, Mansaray, I S, Marah, W S, Massaquoi, M J, Nabie, A, Saidu, N S, Samai, I, Tengheh, J N, Turay, A S, Fornah, A, Sesay, F, Sow, A, Swaray, E, Mansaray, F, Ade-Cole, T, Bangura, L M, Conteh, M L, Koroma, A M, Koroma, M, Sam, A, Scott, T, Sessie, T, Sunders, J-H C, Turay, S I-S, Weekes, J, Sheku, M, Gibson, L, Kowuor, D, Ahamed, I, Allieu, W, Kabba, D U, Kamara, F J, Kebbie, M S, Pessima, M, Wurie, A, Bah, F, Bangura, A I, Bangura, R A S, Blango, L, Boima, S, Conteh, M, Conteh, Y, Daramy, M L, Fofanah, O, George, E, Hanson, T F, Jalloh, M I, Kalawa, M, Kamara, A M, Kamara, F E, Kamara, G M, Kamara, H M, Kamara, P B D, Kamara, R T, Kamara, R, Kanneh, D P, Komeh, I, Kuyateh, M, Mansaray, F F, Mansaray, M M, Sillah, A B, Tarawally, M A, Turya, O S, Yawmah, J B, Leigh, B, Watson-Jones, D, Greenwood, B, Samai, M H, Deen, G F, Marke, D, Sesay, T, Piot, P, Smith, P, Edmunds, J, Lees, S, Larson, H, Weiss, H, Wilson, P, Phillips, R, Maxwell, C, Ishola, D, Afolabi, M, Baiden, F, Akoo, P, Owusu-Kyei, K, Tindanbil, D, Bower, H, Stuart, J, Bah, O M, Rogers, B T, Serry-Bangura, A, Swaray, I B, Bangura, A, David, I J, Davies, D G M, Kallon, J A, Kamara, A B, Kamara, I F, Kamara, M M, Morovia, F E, Suma, F B, Thompson, F, Murray, M, Kakay, O, Suma, F, Sesay, I, Foster, J, Manno, D, Gallagher, K, Cox, S, Howard, N, Cesay, M, Torrani, P, Sharma, S, Snowden, E, Banks, T, Harber, T, Brown, J, Howard, K, Melton, N, Malcolm, S, Welsh, S, Eggo, R, Jendrossek, M, Pearson, C, Offergeld, K, Ferrault, C, Van Alst, M, Mahajan, N, Van Looveren, M, Van Ballaert, S, De Cnodder, T, Grobler, N, Roza, L, Liberi, T, Armishaw, L, Verkleij, C, Henrick, T, Banaszkiewicz, A, Lowe, B, Awuondo, K, Hafezi, H, Hancox, E, Kohn, B, Tuda, G O, Bangura, G, Kroma, M T, Fofanah, L, Pessima, A, Rogers, M, Sheriff, O, Ajala, T W, Fangawa, J, Foday Jr, S, Koroma, I S F, Mansaray, B, Mansaray, H A, Sesay, K, Charles, M K, Heroe, P C, Lamin Karbo, M, Yansaneh, I S, Gogo Egoeh, S, Trye, A, Amponsah, M, Donelson, L, Sylvester, T, Owira, V, Onyuka, G, Nambuchi, L, Oburu, A, Apollo, D, Vandi, L, Alghali, N D, Bah, A, Bangura, I J, Cole, A C, Fofanah, S, Jalloh, H U, Jalloh, K F N, Jalloh, N, Kabba, H U, Kabba, J N, Kabba, M, Kamara, J S, Kanjie, F, Kanu, A P, Kargbo, I, Kassa-Koroma, G, Koroma, S B, Sankoh, A, Sankoh, T, Sesay, O D, Wilhem, H, Williams, C T, Bangura, I, Ben-Rogers, Y, Jamboria, F J, Kamara, N, Kanawah, I, Kargbo, A T, Swaray, I, Amara, L, Bundu, I, Jakema, H B, Kamara, K, Sheku, M F, Adeleye, Q, Akhigbe, I, Bakalemwa, R, Chami, N P, Altmann, L, Kamara, B, van Roey, K, Conteh, P, Samura, M, Gandie, V, Marrah, M, Moinina, E, Kalokoh, J, Bosompem, S, Hilton, T, Jusu, M O, Borboh, P, Brima, A S, Caulker, A F Y, Kallon, A, Koroma, B, Macauley, R C, Saquee, T M D, Williams, H I, Bangura, A R, Fornah, J, Idriss, B, Sillah, M, Mackay, W, Aleghen, B, Murray, T, Edem-Hotah, J, Fatorma, T, Amara, F, Bangura, S, Bonnie, E, Sannoh, M, Donaldson, A, Ndingi, S, Nyaberi, D, Pereira, M, Rothwell, A, Vy, V, Nyallay, L, Fombah, A, Saidu, S, Dambo, T P, Fakaba, P J, Fatorma, M M E, Freeman, R H, Johnson, C L, Kogba, D B, Lahai, A, Vincent, W, Yambasu, N, Bangura, M, Tengbeh, A, Kabia, R, Nyakoi, A M, Callaghan, M, Enria, L, Lee, S, Afolabi, Muhammed O, Ishola, David, Manno, Daniela, Keshinro, Babajide, Bockstal, Viki, Rogers, Baimba, Owusu-Kyei, Kwabena, Serry-Bangura, Alimamy, Swaray, Ibrahim, Lowe, Brett, Kowuor, Dickens, Baiden, Frank, Mooney, Thomas, Smout, Elizabeth, Köhn, Brian, Otieno, Godfrey T, Jusu, Morrison, Foster, Julie, Samai, Mohamed, Deen, Gibrilla Fadlu, Larson, Heidi, Lees, Shelley, Goldstein, Neil, Gallagher, Katherine E, Gaddah, Auguste, Heerwegh, Dirk, Callendret, Benoit, Luhn, Kerstin, Robinson, Cynthia, Greenwood, Brian, Leyssen, Maarten, Douoguih, Macaya, Leigh, Bailah, and Watson-Jones, Deborah

Published
2022
Full Text
View/download PDF

3. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

Author

Kargbo, M, Bockarie, E, James, N L, Kabbah, A, Kamara, A, Koroma, K H, Langley, S O, William, N, Kessebeh, R, Mooney, T, Conteh, L, Smout, E, Allieu, K, Bangura, K, Bangura, M S, Bangura, M A, Jalloh, H, Jalloh, A B, Kamara, I, Kamara, M, Konteh, A, Koroma, S, Marrah, C, Sesay, M, Sesay, M T, Deen, A T, Jalloh, A, Kaimbay, R M, Kain, D, Kamara, E L, Kamara, M P, Kamara, O J, Kamara, S L M, Kanneh, M, Koroma, A H, Lahai, D, Mansaray, I S, Marah, W S, Massaquoi, M J, Nabie, A, Saidu, N S, Samai, I, Tengheh, J N, Turay, A S, Fornah, A, Sesay, F, Sow, A, Swaray, E, Mansaray, F, Ade-Cole, T, Bangura, L M, Conteh, M L, Koroma, A M, Koroma, M, Sam, A, Scott, T, Sessie, T, Sunders, J-H C, Turay, S I-S, Weekes, J, Sheku, M, Gibson, L, Kowuor, D, Ahamed, I, Allieu, W, Kabba, D U, Kamara, F J, Kebbie, M S, Pessima, M, Wurie, A, Bah, F, Bangura, A I, Bangura, R A S, Blango, L, Boima, S, Conteh, M, Conteh, Y, Daramy, M L, Fofanah, O, George, E, Hanson, T F, Jalloh, M I, Kalawa, M, Kamara, A M, Kamara, F E, Kamara, G M, Kamara, H M, Kamara, P B D, Kamara, R T, Kamara, R, Kanneh, D P, Komeh, I, Kuyateh, M, Mansaray, F F, Mansaray, M M, Sillah, A B, Tarawally, M A, Turya, O S, Yawmah, J B, Leigh, B, Watson-Jones, D, Greenwood, B, Samai, M H, Deen, G F, Marke, D, Piot, P, Smith, P, Edmunds, J, Lees, S, Larson, H, Weiss, H, Wilson, P, Maxwell, C, Ishola, D, Afolabi, M, Baiden, F, Akoo, P, Owusu-Kyei, K, Tindanbil, D, Bower, H, Stuart, J, Bah, O M, Rogers, B T, Serry-Bangura, A, Swaray, I B, Bangura, A, David, I J, Davies, D G M, Kallon, J A, Kamara, A B, Kamara, I F, Kamara, M M, Morovia, F E, Suma, F B, Thompson, F, Murray, M, Sesay, I, Kakay, O, Suma, F, Foster, J, Philips, R, Manno, D, Gallager, K, Cox, S, Howard, N, Cesay, M, Torrani, P, Sharma, S, Snowden, E, Banks, T, Harber, T, Brown, J, Howard, K, Melton, N, Malcolm, S, Welsh, S, Eggo, R, Jendrossek, M, Pearson, C, Van Hoof, J, Douoguih, M, Offergelt, K, Robinson, C, Keshinro, B, Van Alst, M, Mahajan, N, Bockstal, V, Goldstein, N, Gaddah, A, Heerwegh, D, Luhn, K, Leyssen, M, Lowe, B, Awuondo, K, Hafezi, H, Hancox, E, Kohn, B, Tuda, G O, Koroma, F, Bangura, G, Kroma, M T, Fofanah, L, Pessima, A, Rogers, M, Sheriff, O, Ajala, T W, Fangawa, J, Foday Jr, S, Jabbie, I, Mansaray, B, Mansaray, H A, Sesay, K, Charles, M K, Heroe, P C, Karbo, M L, Yansaneh, IS, Egoeh, S G, Trye, A, Amponsah, M, Alghali, N D, Bah, A, Bangura, IJ, Cole, A C, Fofanah, K, Fofanah, S, Jalloh, H U, Jalloh, K F N, Jalloh, N, Kabba, H U, Kabba, J N, Kabba, M, Kamara, J S, Kanjie, F, Kanu, A P, Kargbo, I, Kassa-Koroma, G, Koroma, S B, Sankoh, A, Sankoh, T, Sesay, O D, Wilhem, H, Williams, C T, Bangura, I, Ben-Rogers, Y, Jamboria, F J, Kamara, N, Kanawah, I, Kargbo, A T, Swaray, I, Amara, L, Bundu, I, Jakema, H B, Kamara, K, Sheku, M F, Adeleye, Q, Akhigbe, I, Bakalemwa, R, Chami, N P, Sylvester, T, Altmann, L, Kamara, B, van Roey, K, Conteh, P, Samura, M, Gandie, V, Marrah, M, Moinina, E, Kalokoh, J, Bangura, M I, Bosompem, S, Hilton, T, Jusu, M O, Borboh, P, Brima, A S, Caulker, A F Y, Kallon, A, Koroma, B, Macauley, RC, Saquee, T M D, Williams, H I, Bangura, A R, Fornah, J, Idriss, B, Sillah, M, Mackay, W, Aleghen, B, Murray, T, Edem-Hotah, J, Fatorma, T, Amara, F, Bangura, S, Bonnie, E, Sannoh, M, Donaldson, A, Ndingi, S, Nyaberi, D, Pereira, M, Rothwell, A, Vy, V, Nyallay, L, Fombah, A, Saidu, S, Connor, N, Dambo, T P, Fakaba, P J, Fatorma, M M E, Johnson, C L, Kogba, D B, Lahai, A, Vincent, W, Yambasu, N, Bangura, M, Tengbeh, A, Kabia, R, Nyakoi, AM, Callaghan, M, Enria, L, Lee, S, Ishola, David, Manno, Daniela, Afolabi, Muhammed O, Keshinro, Babajide, Bockstal, Viki, Rogers, Baimba, Owusu-Kyei, Kwabena, Serry-Bangura, Alimamy, Swaray, Ibrahim, Lowe, Brett, Kowuor, Dickens, Baiden, Frank, Mooney, Thomas, Smout, Elizabeth, Köhn, Brian, Otieno, Godfrey T, Jusu, Morrison, Foster, Julie, Samai, Mohamed, Deen, Gibrilla Fadlu, Larson, Heidi, Lees, Shelley, Goldstein, Neil, Gallagher, Katherine E, Gaddah, Auguste, Heerwegh, Dirk, Callendret, Benoit, Luhn, Kerstin, Robinson, Cynthia, Leyssen, Maarten, Greenwood, Brian, Douoguih, Macaya, Leigh, Bailah, and Watson-Jones, Deborah

Published
2022
Full Text
View/download PDF

4. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

Author

Choi, Edward Man-Lik, primary, Lacarra, Boris, additional, Afolabi, Muhammed O, additional, Ale, Boni Maxime, additional, Baiden, Frank, additional, Bétard, Christine, additional, Foster, Julie, additional, Hamzé, Benjamin, additional, Schwimmer, Christine, additional, Manno, Daniela, additional, D’Ortenzio, Eric, additional, Ishola, David, additional, Keita, Cheick Mohamed, additional, Keshinro, Babajide, additional, Njie, Yusupha, additional, van Dijck, Wim, additional, Gaddah, Auguste, additional, Anumendem, Dickson, additional, Lowe, Brett, additional, Vatrinet, Renaud, additional, Lawal, Bolarinde Joseph, additional, Otieno, Godfrey T, additional, Samai, Mohamed, additional, Deen, Gibrilla Fadlu, additional, Swaray, Ibrahim Bob, additional, Kamara, Abu Bakarr, additional, Kamara, Michael Morlai, additional, Diagne, Mame Aminata, additional, Kowuor, Dickens, additional, McLean, Chelsea, additional, Leigh, Bailah, additional, Beavogui, Abdoul Habib, additional, Leyssen, Maarten, additional, Luhn, Kerstin, additional, Robinson, Cynthia, additional, Douoguih, Macaya, additional, Greenwood, Brian, additional, Thiébaut, Rodolphe, additional, Watson-Jones, Deborah, additional, Mooney, T, additional, Conteh, L, additional, Bangura, MS, additional, Bangura, MA, additional, Jalloh, H, additional, Kamara, I, additional, Kamara, M, additional, Koroma, S, additional, Sesay, M, additional, Sesay, MT, additional, Deen, AT, additional, Kamara, A, additional, Kamara, EL, additional, Kamara, SLM, additional, Koroma, AH, additional, Mansaray, IS, additional, Massaquoi, MJ, additional, Nabie, A, additional, Kowuor, D, additional, Njie, Y, additional, Odeny, L, additional, Sheku, M, additional, Jalloh, AB, additional, Sow, A, additional, Swaray, E, additional, Mansaray, F, additional, Sessie, T, additional, Sunders, J-HC, additional, Turay, SI-S, additional, Weekes, J, additional, Pessima, M, additional, Wurie, A, additional, Conteh, M, additional, Jalloh, MI, additional, Kamara, PBD, additional, Kanneh, DP, additional, Kanneh, M, additional, Komeh, I, additional, Koroma, M, additional, Kuyateh, M, additional, Mansaray, FF, additional, Leigh, B, additional, Watson-Jones, D, additional, Samai, M, additional, Deen, GF, additional, Sesay, T, additional, Piot, P, additional, Greenwood, B, additional, Lees, S, additional, Larson, H, additional, Afolabi, M, additional, Ishola, D, additional, Baiden, F, additional, Faye, F, additional, Tindanbil, D, additional, Kamara, MM, additional, Swaray, IB, additional, Bangura, A, additional, Kamara, AB, additional, Morovia, FE, additional, Kallon, JA, additional, Murray, M, additional, Sesay, F, additional, Suma, F, additional, Sesay, IG, additional, Choi, EM, additional, Manno, D, additional, Foster, J, additional, Rwezaula, R, additional, Akhigbe, I, additional, Adetola, H, additional, Kamara, B, additional, Lowe, B, additional, Lawal, B, additional, Kohn, B, additional, Tuda, GO, additional, Koroma, F, additional, Bangura, G, additional, Kroma, MT, additional, Fofanah, L, additional, Pessima, A, additional, Rogers, M, additional, Sheriff, O, additional, Fangawa, J, additional, Foday, S, additional, Jabbie, I, additional, Mansaray, HA, additional, Sesay, K, additional, Jakema, HB, additional, Sheku, MF, additional, Jalloh, KFN, additional, Kabba, M, additional, Kanjie, F, additional, Kanu, AP, additional, Kassa-Koroma, G, additional, Jusu, M, additional, Koroma, B, additional, Borboh, P, additional, Kallon, A, additional, van Roey, K, additional, Conteh, P, additional, Samura, M, additional, Gandie, V, additional, Marrah, M, additional, Kalokoh, J, additional, Bangura, MI, additional, Connor, N, additional, Saidu, S, additional, Turay, AS, additional, Lahai, A, additional, Johnson, CL, additional, Kogba, DB, additional, Vincent, W, additional, Bangura, M, additional, Tengbeh, A, additional, Bangura, K, additional, Kabia, R, additional, Nyakoi, AM, additional, Lee, S, additional, Nyaberi, D, additional, Ndingi, S, additional, Nyallay, L, additional, Bangura, AR, additional, Idriss, B, additional, Sillah, M, additional, Mackay, W, additional, Murray, T, additional, Edem-Hotah, J, additional, Fatorma, T, additional, Bangura, S, additional, Bonnie, E, additional, Sannoh, M, additional, Malcolm, S, additional, Brown, J, additional, Snowden, E, additional, Howard, K, additional, Ojugo, A, additional, Massin-Shepherd, C, additional, BEAVOGUI, AH, additional, KEITA, CM, additional, CAMARA, OK, additional, GUILAVOGUI, JPY, additional, BAH, H, additional, SAMOURA, MA, additional, MUAMBA, D, additional, SEMAKUBA, B, additional, CAMARA, AK, additional, KABA, AS, additional, BERERD-CAMARA, M, additional, YARADOUNO, M, additional, DECHENAUD, M, additional, CAMARA, MT, additional, TAMBALOU, J, additional, HABA, M, additional, DIALLO, SD, additional, THEA, A, additional, DOUMBOUYA, N, additional, FOFANA, ML, additional, BEAVOGUI, M, additional, CAMARA, AA, additional, BEAVOGUI, JT, additional, DIOUF, W, additional, AUGIER, A, additional, BARTE DE SAINTE FARE, E, additional, SIVAHERA MUYISA, B, additional, SANI, S, additional, VATRINET, R, additional, HAMZE, B, additional, LACARRA, B, additional, D’ORTENZIO, E, additional, ALE, B, additional, BETARD, C, additional, RICHERT, L, additional, OULAI, D, additional, KANTE, M, additional, SOUTTHIPHONG, A-A, additional, SCHWIMMER, C, additional, THIÉBAUT, R, additional, OTTAVI, A, additional, COUFFIN-CADIERGUES, S, additional, ESPEROU, H, additional, Chai, SP, additional, Buth, W, additional, Offergeld, K, additional, Menten, A, additional, Hammoud, N, additional, De Ridder, S, additional, Sellecchia, R, additional, in ’t Veld, R, additional, Fogap, N, additional, Anumendem, D, additional, Stapleton, H, additional, Reijns, T, additional, Haydon, J, additional, Roza, L, additional, Sawyer, B, additional, Hoda, S, additional, Yee, J, additional, De Cnodder, T, additional, Hubin, E, additional, Telen, L, additional, Desai, J, additional, Bennet, M, additional, Pawlowski, M, additional, van Gils, N, additional, Boeykens, N, additional, Kwasniak, A, additional, Ligthart, M, additional, Van Roey, G, additional, Fernandez, E, additional, Gaddah, A, additional, van Dijck, W, additional, Jingshuang, S, additional, Randrasana, S, additional, Artis, C, additional, Akinbinu, A, additional, Poretti, A, additional, Van Ballaert, S, additional, Harris, M, additional, Van Looveren, M, additional, Brandt, P, additional, Robinson, C, additional, Bockstal, V, additional, McLean, C, additional, Versteege, I, additional, Ferrault, C, additional, Kaminski, A, additional, Vergauwen, H, additional, Kerama, CI, additional, Forcheh, CA, additional, DiMondi, CV, additional, Stewart, L, additional, Meurer, J, additional, Beounitis, A, additional, Peeters, J, additional, Su, C, additional, Keshinro, B, additional, Delport, C, additional, Sharkie, E, additional, Zhang, J, additional, Du, C, additional, Hu, K, additional, Strydom, A, additional, Bezem-Aviv, I, additional, Wachnicka, A, additional, Kumar, P, additional, Cheng, S, additional, and Kang, K, additional

Published
2023
Full Text
View/download PDF

6. The impact of the COVID-19 pandemic on the provision & utilisation of primary health care services in Goma, Democratic Republic of the Congo, Kambia district, Sierra Leone & Masaka district, Uganda

Author

Kasonia, K., primary, Tindanbil, D., additional, Kitonsa, J., additional, Baisley, K., additional, Zalwango, F., additional, Enria, L., additional, Mansaray, A., additional, James, M., additional, Nije, Y., additional, Tata, D. Tetsa, additional, Lawal, B. J., additional, Drammeh, A., additional, Lowe, B., additional, Mukadi-Bamuleka, D., additional, Mounier-Jack, S., additional, Nakiyimba, F., additional, Obady, P., additional, Muhavi, J., additional, Bangura, J. S., additional, Greenwood, B., additional, Samai, M., additional, Leigh, B., additional, Watson-Jones, D., additional, Kavunga-Membo, H., additional, Ruzagira, E., additional, and Gallagher, K. E., additional

Published
2023
Full Text
View/download PDF

8. Protection, health seeking, or a laissez-passer: Participants’ decision-making in an EVD vaccine trial in the eastern Democratic Republic of the Congo

Author

James, M, Kasereka, JG, Kasiwa, B, Kavunga-Membo, H, Kambale, K, Grais, R, Muyembe-Tamfum, J-J, Bausch, DG, Watson-Jones, D, and Lees, S

Subjects
Health (social science), History and Philosophy of Science
Abstract

During the 10th Ebola virus disease (EVD) epidemic in the eastern Democratic Republic of the Congo (DRC) (2018–2020), two experimental EVD vaccines were deployed in North Kivu. This province has been at the centre of conflict in the region for the last 25 years. Amidst ambivalence towards protracted foreign intervention and controversy about introducing two experimental vaccines, the existing literature has focused on mistrust and ‘resistance’ towards the Ebola response and vaccines. In this article, we examine why people in the eastern DRC did decide to volunteer for a trial of a second EVD vaccine in North Kivu, despite the controversy. Drawing on ethnographic observation, interviews, and focus groups with trial participants conducted between September 2020 and April 2021, we analyse three motivations for participating: protection, health seeking, and expectations surrounding travel requirements. We make three points. First, participation in vaccine trials may be understood locally to have advantages which have not been considered by the trial, because they go beyond medical considerations and are specific to a particular social setting. Second, despite much of the literature focusing on a causal relationship between rumours and ‘vaccine hesitancy’, some rumours may in fact encourage participation. Third, material objects associated with trial participation - such as participant vaccine cards - can hold social and political meaning beyond the confines of the vaccine clinic, and influence decisions surrounding participation. Empirical investigation of how medical interventions become entangled in political economies is essential to understanding the perceived functions of participation, and thus the reasons why people volunteer in clinical trials. Participants' narratives about their decision-making provide an insight into how international bioethical debates interact with, but may also stand apart from, the situated social and economic realities driving decision-making around clinical trials on the ground. This highlights the need for ethical approaches that foreground the political, social, and economic context.

Published
2023

9. The impact of the COVID-19 pandemic on the provision & utilisation of primary health care services in Goma, Democratic Republic of the Congo, Kambia district, Sierra Leone & Masaka district, Uganda

Author

Kasonia, K, primary, Tindanbil, D, additional, Kitonsa, J, additional, Baisley, K, additional, Zalwango, F, additional, Enria, L, additional, Mansaray, A, additional, James, M, additional, Nije, Y, additional, Tata, D Tetsa, additional, Lawal, B J, additional, Drammeh, A, additional, Lowe, B, additional, Mukadi-Bamuleka, D, additional, Mounier-Jack, S, additional, Nakiyimba, F, additional, Obady, P, additional, Muhavi, J, additional, Bangura, J S, additional, Greenwood, B, additional, Samai, M, additional, Leigh, B, additional, Watson-Jones, D, additional, Kavunga-Membo, H, additional, Ruzagira, E, additional, and Gallagher, K E., additional

Published
2022
Full Text
View/download PDF

10. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

Author

Ishola, David, primary, Manno, Daniela, additional, Afolabi, Muhammed O, additional, Keshinro, Babajide, additional, Bockstal, Viki, additional, Rogers, Baimba, additional, Owusu-Kyei, Kwabena, additional, Serry-Bangura, Alimamy, additional, Swaray, Ibrahim, additional, Lowe, Brett, additional, Kowuor, Dickens, additional, Baiden, Frank, additional, Mooney, Thomas, additional, Smout, Elizabeth, additional, Köhn, Brian, additional, Otieno, Godfrey T, additional, Jusu, Morrison, additional, Foster, Julie, additional, Samai, Mohamed, additional, Deen, Gibrilla Fadlu, additional, Larson, Heidi, additional, Lees, Shelley, additional, Goldstein, Neil, additional, Gallagher, Katherine E, additional, Gaddah, Auguste, additional, Heerwegh, Dirk, additional, Callendret, Benoit, additional, Luhn, Kerstin, additional, Robinson, Cynthia, additional, Leyssen, Maarten, additional, Greenwood, Brian, additional, Douoguih, Macaya, additional, Leigh, Bailah, additional, Watson-Jones, Deborah, additional, Kargbo, M, additional, Bockarie, E, additional, James, N L, additional, Kabbah, A, additional, Kamara, A, additional, Koroma, K H, additional, Langley, S O, additional, William, N, additional, Kessebeh, R, additional, Mooney, T, additional, Conteh, L, additional, Smout, E, additional, Allieu, K, additional, Bangura, K, additional, Bangura, M S, additional, Bangura, M A, additional, Jalloh, H, additional, Jalloh, A B, additional, Kamara, I, additional, Kamara, M, additional, Konteh, A, additional, Koroma, S, additional, Marrah, C, additional, Sesay, M, additional, Sesay, M T, additional, Deen, A T, additional, Jalloh, A, additional, Kaimbay, R M, additional, Kain, D, additional, Kamara, E L, additional, Kamara, M P, additional, Kamara, O J, additional, Kamara, S L M, additional, Kanneh, M, additional, Koroma, A H, additional, Lahai, D, additional, Mansaray, I S, additional, Marah, W S, additional, Massaquoi, M J, additional, Nabie, A, additional, Saidu, N S, additional, Samai, I, additional, Tengheh, J N, additional, Turay, A S, additional, Fornah, A, additional, Sesay, F, additional, Sow, A, additional, Swaray, E, additional, Mansaray, F, additional, Ade-Cole, T, additional, Bangura, L M, additional, Conteh, M L, additional, Koroma, A M, additional, Koroma, M, additional, Sam, A, additional, Scott, T, additional, Sessie, T, additional, Sunders, J-H C, additional, Turay, S I-S, additional, Weekes, J, additional, Sheku, M, additional, Gibson, L, additional, Kowuor, D, additional, Ahamed, I, additional, Allieu, W, additional, Kabba, D U, additional, Kamara, F J, additional, Kebbie, M S, additional, Pessima, M, additional, Wurie, A, additional, Bah, F, additional, Bangura, A I, additional, Bangura, R A S, additional, Blango, L, additional, Boima, S, additional, Conteh, M, additional, Conteh, Y, additional, Daramy, M L, additional, Fofanah, O, additional, George, E, additional, Hanson, T F, additional, Jalloh, M I, additional, Kalawa, M, additional, Kamara, A M, additional, Kamara, F E, additional, Kamara, G M, additional, Kamara, H M, additional, Kamara, P B D, additional, Kamara, R T, additional, Kamara, R, additional, Kanneh, D P, additional, Komeh, I, additional, Kuyateh, M, additional, Mansaray, F F, additional, Mansaray, M M, additional, Sillah, A B, additional, Tarawally, M A, additional, Turya, O S, additional, Yawmah, J B, additional, Leigh, B, additional, Watson-Jones, D, additional, Greenwood, B, additional, Samai, M H, additional, Deen, G F, additional, Marke, D, additional, Piot, P, additional, Smith, P, additional, Edmunds, J, additional, Lees, S, additional, Larson, H, additional, Weiss, H, additional, Wilson, P, additional, Maxwell, C, additional, Ishola, D, additional, Afolabi, M, additional, Baiden, F, additional, Akoo, P, additional, Owusu-Kyei, K, additional, Tindanbil, D, additional, Bower, H, additional, Stuart, J, additional, Bah, O M, additional, Rogers, B T, additional, Serry-Bangura, A, additional, Swaray, I B, additional, Bangura, A, additional, David, I J, additional, Davies, D G M, additional, Kallon, J A, additional, Kamara, A B, additional, Kamara, I F, additional, Kamara, M M, additional, Morovia, F E, additional, Suma, F B, additional, Thompson, F, additional, Murray, M, additional, Sesay, I, additional, Kakay, O, additional, Suma, F, additional, Foster, J, additional, Philips, R, additional, Manno, D, additional, Gallager, K, additional, Cox, S, additional, Howard, N, additional, Cesay, M, additional, Torrani, P, additional, Sharma, S, additional, Snowden, E, additional, Banks, T, additional, Harber, T, additional, Brown, J, additional, Howard, K, additional, Melton, N, additional, Malcolm, S, additional, Welsh, S, additional, Eggo, R, additional, Jendrossek, M, additional, Pearson, C, additional, Van Hoof, J, additional, Douoguih, M, additional, Offergelt, K, additional, Robinson, C, additional, Keshinro, B, additional, Van Alst, M, additional, Mahajan, N, additional, Bockstal, V, additional, Goldstein, N, additional, Gaddah, A, additional, Heerwegh, D, additional, Luhn, K, additional, Leyssen, M, additional, Lowe, B, additional, Awuondo, K, additional, Hafezi, H, additional, Hancox, E, additional, Kohn, B, additional, Tuda, G O, additional, Koroma, F, additional, Bangura, G, additional, Kroma, M T, additional, Fofanah, L, additional, Pessima, A, additional, Rogers, M, additional, Sheriff, O, additional, Ajala, T W, additional, Fangawa, J, additional, Foday Jr, S, additional, Jabbie, I, additional, Mansaray, B, additional, Mansaray, H A, additional, Sesay, K, additional, Charles, M K, additional, Heroe, P C, additional, Karbo, M L, additional, Yansaneh, IS, additional, Egoeh, S G, additional, Trye, A, additional, Amponsah, M, additional, Alghali, N D, additional, Bah, A, additional, Bangura, IJ, additional, Cole, A C, additional, Fofanah, K, additional, Fofanah, S, additional, Jalloh, H U, additional, Jalloh, K F N, additional, Jalloh, N, additional, Kabba, H U, additional, Kabba, J N, additional, Kabba, M, additional, Kamara, J S, additional, Kanjie, F, additional, Kanu, A P, additional, Kargbo, I, additional, Kassa-Koroma, G, additional, Koroma, S B, additional, Sankoh, A, additional, Sankoh, T, additional, Sesay, O D, additional, Wilhem, H, additional, Williams, C T, additional, Bangura, I, additional, Ben-Rogers, Y, additional, Jamboria, F J, additional, Kamara, N, additional, Kanawah, I, additional, Kargbo, A T, additional, Swaray, I, additional, Amara, L, additional, Bundu, I, additional, Jakema, H B, additional, Kamara, K, additional, Sheku, M F, additional, Adeleye, Q, additional, Akhigbe, I, additional, Bakalemwa, R, additional, Chami, N P, additional, Sylvester, T, additional, Altmann, L, additional, Kamara, B, additional, van Roey, K, additional, Conteh, P, additional, Samura, M, additional, Gandie, V, additional, Marrah, M, additional, Moinina, E, additional, Kalokoh, J, additional, Bangura, M I, additional, Bosompem, S, additional, Hilton, T, additional, Jusu, M O, additional, Borboh, P, additional, Brima, A S, additional, Caulker, A F Y, additional, Kallon, A, additional, Koroma, B, additional, Macauley, RC, additional, Saquee, T M D, additional, Williams, H I, additional, Bangura, A R, additional, Fornah, J, additional, Idriss, B, additional, Sillah, M, additional, Mackay, W, additional, Aleghen, B, additional, Murray, T, additional, Edem-Hotah, J, additional, Fatorma, T, additional, Amara, F, additional, Bangura, S, additional, Bonnie, E, additional, Sannoh, M, additional, Donaldson, A, additional, Ndingi, S, additional, Nyaberi, D, additional, Pereira, M, additional, Rothwell, A, additional, Vy, V, additional, Nyallay, L, additional, Fombah, A, additional, Saidu, S, additional, Connor, N, additional, Dambo, T P, additional, Fakaba, P J, additional, Fatorma, M M E, additional, Johnson, C L, additional, Kogba, D B, additional, Lahai, A, additional, Vincent, W, additional, Yambasu, N, additional, Bangura, M, additional, Tengbeh, A, additional, Kabia, R, additional, Nyakoi, AM, additional, Callaghan, M, additional, Enria, L, additional, and Lee, S, additional

Published
2022
Full Text
View/download PDF

11. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

Author

Afolabi, Muhammed O, primary, Ishola, David, additional, Manno, Daniela, additional, Keshinro, Babajide, additional, Bockstal, Viki, additional, Rogers, Baimba, additional, Owusu-Kyei, Kwabena, additional, Serry-Bangura, Alimamy, additional, Swaray, Ibrahim, additional, Lowe, Brett, additional, Kowuor, Dickens, additional, Baiden, Frank, additional, Mooney, Thomas, additional, Smout, Elizabeth, additional, Köhn, Brian, additional, Otieno, Godfrey T, additional, Jusu, Morrison, additional, Foster, Julie, additional, Samai, Mohamed, additional, Deen, Gibrilla Fadlu, additional, Larson, Heidi, additional, Lees, Shelley, additional, Goldstein, Neil, additional, Gallagher, Katherine E, additional, Gaddah, Auguste, additional, Heerwegh, Dirk, additional, Callendret, Benoit, additional, Luhn, Kerstin, additional, Robinson, Cynthia, additional, Greenwood, Brian, additional, Leyssen, Maarten, additional, Douoguih, Macaya, additional, Leigh, Bailah, additional, Watson-Jones, Deborah, additional, Kargbo, M, additional, Bockarie, E, additional, James, N L, additional, Kabbah, A, additional, Kamara, A, additional, Koroma, K H, additional, Langley, S O, additional, William, N, additional, Kessebeh, R, additional, Mooney, T, additional, Conteh, L, additional, Smout, E, additional, Allieu, K, additional, Bangura, K, additional, Bangura, M S, additional, Bangura, M A, additional, Jalloh, H, additional, Jalloh, A B, additional, Kamara, I, additional, Kamara, M, additional, Konteh, A, additional, Koroma, S, additional, Marrah, C, additional, Sesay, M, additional, Sesay, M T, additional, Deen, A T, additional, Jalloh, A, additional, Kaimbay, R M, additional, Kain, D, additional, Kamara, E L, additional, Kamara, M P, additional, Kamara, O J, additional, Kamara, S L M, additional, Kanneh, M, additional, Koroma, A H, additional, Lahai, D, additional, Mansaray, I S, additional, Marah, W S, additional, Massaquoi, M J, additional, Nabie, A, additional, Saidu, N S, additional, Samai, I, additional, Tengheh, J N, additional, Turay, A S, additional, Fornah, A, additional, Sesay, F, additional, Sow, A, additional, Swaray, E, additional, Mansaray, F, additional, Ade-Cole, T, additional, Bangura, L M, additional, Conteh, M L, additional, Koroma, A M, additional, Koroma, M, additional, Sam, A, additional, Scott, T, additional, Sessie, T, additional, Sunders, J-H C, additional, Turay, S I-S, additional, Weekes, J, additional, Sheku, M, additional, Gibson, L, additional, Kowuor, D, additional, Ahamed, I, additional, Allieu, W, additional, Kabba, D U, additional, Kamara, F J, additional, Kebbie, M S, additional, Pessima, M, additional, Wurie, A, additional, Bah, F, additional, Bangura, A I, additional, Bangura, R A S, additional, Blango, L, additional, Boima, S, additional, Conteh, M, additional, Conteh, Y, additional, Daramy, M L, additional, Fofanah, O, additional, George, E, additional, Hanson, T F, additional, Jalloh, M I, additional, Kalawa, M, additional, Kamara, A M, additional, Kamara, F E, additional, Kamara, G M, additional, Kamara, H M, additional, Kamara, P B D, additional, Kamara, R T, additional, Kamara, R, additional, Kanneh, D P, additional, Komeh, I, additional, Kuyateh, M, additional, Mansaray, F F, additional, Mansaray, M M, additional, Sillah, A B, additional, Tarawally, M A, additional, Turya, O S, additional, Yawmah, J B, additional, Leigh, B, additional, Watson-Jones, D, additional, Greenwood, B, additional, Samai, M H, additional, Deen, G F, additional, Marke, D, additional, Sesay, T, additional, Piot, P, additional, Smith, P, additional, Edmunds, J, additional, Lees, S, additional, Larson, H, additional, Weiss, H, additional, Wilson, P, additional, Phillips, R, additional, Maxwell, C, additional, Ishola, D, additional, Afolabi, M, additional, Baiden, F, additional, Akoo, P, additional, Owusu-Kyei, K, additional, Tindanbil, D, additional, Bower, H, additional, Stuart, J, additional, Bah, O M, additional, Rogers, B T, additional, Serry-Bangura, A, additional, Swaray, I B, additional, Bangura, A, additional, David, I J, additional, Davies, D G M, additional, Kallon, J A, additional, Kamara, A B, additional, Kamara, I F, additional, Kamara, M M, additional, Morovia, F E, additional, Suma, F B, additional, Thompson, F, additional, Murray, M, additional, Kakay, O, additional, Suma, F, additional, Sesay, I, additional, Foster, J, additional, Manno, D, additional, Gallagher, K, additional, Cox, S, additional, Howard, N, additional, Cesay, M, additional, Torrani, P, additional, Sharma, S, additional, Snowden, E, additional, Banks, T, additional, Harber, T, additional, Brown, J, additional, Howard, K, additional, Melton, N, additional, Malcolm, S, additional, Welsh, S, additional, Eggo, R, additional, Jendrossek, M, additional, Pearson, C, additional, Offergeld, K, additional, Ferrault, C, additional, Van Alst, M, additional, Mahajan, N, additional, Van Looveren, M, additional, Van Ballaert, S, additional, De Cnodder, T, additional, Grobler, N, additional, Roza, L, additional, Liberi, T, additional, Armishaw, L, additional, Verkleij, C, additional, Henrick, T, additional, Banaszkiewicz, A, additional, Lowe, B, additional, Awuondo, K, additional, Hafezi, H, additional, Hancox, E, additional, Kohn, B, additional, Tuda, G O, additional, Bangura, G, additional, Kroma, M T, additional, Fofanah, L, additional, Pessima, A, additional, Rogers, M, additional, Sheriff, O, additional, Ajala, T W, additional, Fangawa, J, additional, Foday Jr, S, additional, Koroma, I S F, additional, Mansaray, B, additional, Mansaray, H A, additional, Sesay, K, additional, Charles, M K, additional, Heroe, P C, additional, Lamin Karbo, M, additional, Yansaneh, I S, additional, Gogo Egoeh, S, additional, Trye, A, additional, Amponsah, M, additional, Donelson, L, additional, Sylvester, T, additional, Owira, V, additional, Onyuka, G, additional, Nambuchi, L, additional, Oburu, A, additional, Apollo, D, additional, Vandi, L, additional, Alghali, N D, additional, Bah, A, additional, Bangura, I J, additional, Cole, A C, additional, Fofanah, S, additional, Jalloh, H U, additional, Jalloh, K F N, additional, Jalloh, N, additional, Kabba, H U, additional, Kabba, J N, additional, Kabba, M, additional, Kamara, J S, additional, Kanjie, F, additional, Kanu, A P, additional, Kargbo, I, additional, Kassa-Koroma, G, additional, Koroma, S B, additional, Sankoh, A, additional, Sankoh, T, additional, Sesay, O D, additional, Wilhem, H, additional, Williams, C T, additional, Bangura, I, additional, Ben-Rogers, Y, additional, Jamboria, F J, additional, Kamara, N, additional, Kanawah, I, additional, Kargbo, A T, additional, Swaray, I, additional, Amara, L, additional, Bundu, I, additional, Jakema, H B, additional, Kamara, K, additional, Sheku, M F, additional, Adeleye, Q, additional, Akhigbe, I, additional, Bakalemwa, R, additional, Chami, N P, additional, Altmann, L, additional, Kamara, B, additional, van Roey, K, additional, Conteh, P, additional, Samura, M, additional, Gandie, V, additional, Marrah, M, additional, Moinina, E, additional, Kalokoh, J, additional, Bosompem, S, additional, Hilton, T, additional, Jusu, M O, additional, Borboh, P, additional, Brima, A S, additional, Caulker, A F Y, additional, Kallon, A, additional, Koroma, B, additional, Macauley, R C, additional, Saquee, T M D, additional, Williams, H I, additional, Bangura, A R, additional, Fornah, J, additional, Idriss, B, additional, Sillah, M, additional, Mackay, W, additional, Aleghen, B, additional, Murray, T, additional, Edem-Hotah, J, additional, Fatorma, T, additional, Amara, F, additional, Bangura, S, additional, Bonnie, E, additional, Sannoh, M, additional, Donaldson, A, additional, Ndingi, S, additional, Nyaberi, D, additional, Pereira, M, additional, Rothwell, A, additional, Vy, V, additional, Nyallay, L, additional, Fombah, A, additional, Saidu, S, additional, Dambo, T P, additional, Fakaba, P J, additional, Fatorma, M M E, additional, Freeman, R H, additional, Johnson, C L, additional, Kogba, D B, additional, Lahai, A, additional, Vincent, W, additional, Yambasu, N, additional, Bangura, M, additional, Tengbeh, A, additional, Kabia, R, additional, Nyakoi, A M, additional, Callaghan, M, additional, Enria, L, additional, and Lee, S, additional

Published
2022
Full Text
View/download PDF

20. Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial

Author

Thomas, R, Burger, R, Harper, A, Kanema, S, Mwenge, L, Vanqa, N, Bell-Mandla, N, Smith, P, Floyd, S, Bock, P, Ayles, H, Beyers, N, Donnell, D, Fidler, S, Hayes, R, Hauck, K, Hargreaves, J, Watson-Jones, D, Godfrey-Faussett, P, Cori, A, Pickles, M, Mandla, N, Yang, B, James, A, Vermaak, R, Makola, N, Hoddinott, G, Naidoo, V, Bond, V, Simwinga, M, Mwinga, A, Kosloff, B, Limbada, M, Bwalya, J, Ngulube, C, Fraser, C, Eshleman, S, Agyei, Y, Cummings, V, Catalano, D, Emel, L, Bunts, L, Noble, H, Burns, D, Kouda, A, Sista, N, Moore, A, White, R, Headen, T, Miller, E, Hinson, K, Vermund, S, Barnes, M, Horn, L, Mwango, A, Baldwin, M, Wolf, S, and Hughes, E

Subjects
lcsh:Public aspects of medicine, virus diseases, lcsh:RA1-1270
Abstract

Background The life expectancy of HIV-positive individuals receiving antiretroviral therapy (ART) is approaching that of HIV-negative people. However, little is known about how these populations compare in terms of health-related quality of life (HRQoL). We aimed to compare HRQoL between HIV-positive and HIV-negative people in Zambia and South Africa. Methods As part of the HPTN 071 (PopART) study, data from adults aged 18–44 years were gathered between Nov 28, 2013, and March 31, 2015, in large cross-sectional surveys of random samples of the general population in 21 communities in Zambia and South Africa. HRQoL data were collected with a standardised generic measure of health across five domains. We used β-distributed multivariable models to analyse differences in HRQoL scores between HIV-negative and HIV-positive individuals who were unaware of their status; aware, but not in HIV care; in HIV care, but who had not initiated ART; on ART for less than 5 years; and on ART for 5 years or more. We included controls for sociodemographic variables, herpes simplex virus type-2 status, and recreational drug use. Findings We obtained data for 19 750 respondents in Zambia and 18 941 respondents in South Africa. Laboratory-confirmed HIV status was available for 19 330 respondents in Zambia and 18 004 respondents in South Africa; 4128 (21%) of these 19 330 respondents in Zambia and 4012 (22%) of 18 004 respondents in South Africa had laboratory-confirmed HIV. We obtained complete HRQoL information for 19 637 respondents in Zambia and 18 429 respondents in South Africa. HRQoL scores did not differ significantly between individuals who had initiated ART more than 5 years previously and HIV-negative individuals, neither in Zambia (change in mean score −0·002, 95% CI −0·01 to 0·001; p=0·219) nor in South Africa (0·000, −0·002 to 0·003; p=0·939). However, scores did differ between HIV-positive individuals who had initiated ART less than 5 years previously and HIV-negative individuals in Zambia (−0·006, 95% CI −0·008 to −0·003; p Interpretation ART is successful in helping to reduce inequalities in HRQoL between HIV-positive and HIV-negative individuals in this general population sample. These findings highlight the importance of improving awareness of HIV status and expanding ART to prevent losses in HRQoL that occur with untreated HIV progression. The gains in HRQoL after individuals initiate ART could be substantial when scaled up to the population level. Funding National Institute of Allergy and Infectious Diseases, National Institute on Drug Abuse, National Institute of Mental Health, President's Emergency Plan for AIDS Relief, International Initiative for Impact Evaluation, the Bill & Melinda Gates Foundation.

Published
2017

21. Estimates of burden and consequences of infants born small for gestational age in low and middle income countries with INTERGROWTH-21 st standard: Analysis of CHERG datasets

Author

Schmiegelow, C., Sania, A., Velaphi, S.C., Kolsteren, P., Fawzi, W., Silveira, M.F., Adair, L.S., Christian, P., Ezzati, M., Baqui, A.H., Mullany, L.C., Tielsch, J.M., Lawn, J.E., Caulfield, L.E., Saville, N., Lee, A.C.C., Huybregts, L., Barros, F.C., Stevens, G.A., Ndyomugyenyi, R., Victora, C.G., Roberfroid, D., Mongkolchati, A., Blencowe, H., Terlouw, D.J., Watson-Jones, D., Humphrey, J., Nien, J.K., Willey, B.A., Manandhar, D., Gonzalez, R., Black, R.E., Rosen, H.E., Kariuki, S., Bhutta, Z.A., Lusingu, J., Clarke, S.E., Kozuki, N., Cousens, S., and Katz, J.

Abstract

Objectives To estimate small for gestational age birth prevalence and attributable neonatal mortality in low and middle income countries with the INTERGROWTH-21 st birth weight standard. Design Secondary analysis of data from the Child Health Epidemiology Reference Group (CHERG), including 14 birth cohorts with gestational age, birth weight, and neonatal follow-up. Small for gestational age was defined as infants weighing less than the 10th centile birth weight for gestational age and sex with the multiethnic, INTERGROWTH-21 st birth weight standard. Prevalence of small for gestational age and neonatal mortality risk ratios were calculated and pooled among these datasets at the regional level. With available national level data, prevalence of small for gestational age and population attributable fractions of neonatal mortality attributable to small for gestational age were estimated. Setting CHERG birth cohorts from 14 population based sites in low and middle income countries. Main outcome measures In low and middle income countries in the year 2012, the number and proportion of infants born small for gestational age; number and proportion of neonatal deaths attributable to small for gestational age; the number and proportion of neonatal deaths that could be prevented by reducing the prevalence of small for gestational age to 10%. Results In 2012, an estimated 23.3 million infants (uncertainty range 17.6 to 31.9; 19.3% of live births) were born small for gestational age in low and middle income countries. Among these, 11.2 million (0.8 to 15.8) were term and not low birth weight (���2500 g), 10.7 million (7.6 to 15.0) were term and low birth weight (

Published
2017
Full Text
View/download PDF

23. Opérationnalisation de la randomisation d’un essai vaccinal en population générale africaine : exemple de l’essai PREVAC (« Partnership for Research on Ebola Vaccination »)

Author

Colin, C., primary, Kirchoff, M., additional, Vallee, D., additional, Thompson, G., additional, Lhomme, E., additional, Thiebaut, R., additional, Pierson, J.F., additional, Watson Jones, D., additional, Leigh, B., additional, Kieh, M., additional, H. Beavogui, A., additional, Yazdanpanah, Y., additional, Richert, L., additional, Wentworth, D., additional, Chêne, G., additional, and Neaton, J., additional

Published
2017
Full Text
View/download PDF

25. The Association between Cervical Human Papillomavirus Infection and Subsequent HIV Acquisition in Tanzanian and Ugandan Women: A Nested Case-Control Study

Author

Gallagher, KE, Baisley, K, Grosskurth, H, Vallely, A, Kapiga, S, Vandepitte, J, Kamali, A, De Sanjose, S, Changalucha, J, Hayes, R, Watson-Jones, D, Gallagher, KE, Baisley, K, Grosskurth, H, Vallely, A, Kapiga, S, Vandepitte, J, Kamali, A, De Sanjose, S, Changalucha, J, Hayes, R, and Watson-Jones, D

Abstract

Objective This study was performed to analyze the associations between cervical human papillomavirus (HPV) infection and human immunodeficiency virus (HIV) acquisition, using cervical samples from previous studies in Tanzania and Uganda. Methods. A total of 161 adult women who acquired HIV infection during follow-up and 464 individually matched HIV-seronegative controls were selected from 5 cohorts of women working in bars and recreational facilities. Stored cervical samples were tested for 37 HPV genotypes, using a polymerase chain reaction assay (Roche Linear Array genotyping assay). Multivariate matched analysis using conditional logistic regression was performed to evaluate HPV infection, persistence, and clearance as predictors of HIV acquisition. Results. HIV seroconverters were significantly more likely than controls to frequently drink alcohol and to be infected with Chlamydia trachomatis, Neisseria gonorrhoeae, or herpes simplex virus type 2. There was no evidence of an association between HIV acquisition and any detectable HPV at the visit prior to HIV seroconversion (adjusted odds ratio, 1.02; 95% confidence interval,. 66-1.57) or between HIV acquisition and persistent HPV infection (defined as 2 positive HPV genotype-specific test results at least 6 months apart), cleared HPV infection (defined as a positive HPV test result followed by negative HPV genotype-specific test result), or newly acquired HPV infection, compared with HPV-negative women. Conclusions. There was no evidence of association between HPV infection status and subsequent HIV acquisition. These results stand in contrast to other observational studies.

Published
2016

46. Adverse birth outcomes in United Republic of Tanzania--impact and prevention of maternal risk factors.

Author

Watson-Jones D, Weiss HA, Changalucha JM, Todd J, Gumodoka B, Bulmer J, Balira R, Ross D, Mugeye K, Hayes R, and Mabey D

Abstract

OBJECTIVE: To determine risk factors for poor birth outcome and their population attributable fractions. METHODS: 1688 women who attended for antenatal care were recruited into a prospective study of the effectiveness of syphilis screening and treatment. All women were screened and treated for syphilis and other reproductive tract infections (RTIs) during pregnancy and followed to delivery to measure the incidence of stillbirth, intrauterine growth retardation (IUGR), low birth weight (LBW) and preterm live birth. FINDINGS: At delivery, 2.7% of 1536 women experienced a stillbirth, 12% of live births were preterm and 8% were LBW. Stillbirth was independently associated with a past history of stillbirth, short maternal stature and anaemia. LBW was associated with short maternal stature, ethnicity, occupation, gravidity and maternal malaria whereas preterm birth was associated with occupation, age of sexual debut, untreated bacterial vaginosis and maternal malaria. IUGR was associated with gravidity, maternal malaria, short stature, and delivering a female infant. In the women who had been screened and treated for syphilis, in between 20 and 34% of women with each outcome was estimated to be attributable to malaria, and 63% of stillbirths were estimated as being attributable to maternal anaemia. Screening and treatment of RTIs was effective and no association was seen between treated RTIs and adverse pregnancy outcomes. CONCLUSION: Maternal malaria and anaemia continue to be significant causes of adverse pregnancy outcome in sub-Saharan Africa. Providing reproductive health services that include treatment of RTIs and prevention of malaria and maternal anaemia to reduce adverse birth outcomes remains a priority. Copyright © 2007 World Health Organization [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

47. High prevalence of trichomoniasis in rural men in Mwanza, Tanzania: results from a population based study

Author

Cleophas-Frisch, B., Watson-Jones, D., Buvé, A., Mayaud, P., Laga, M., Todd, J., Mosha, F., West, B., Grosskurth, H., Hayes, R., Mabey, D., Mugeye, K., and Ndeki, L.

Abstract

Objectives:To measure the prevalence of urethral infections including trichomoniasis in rural Tanzanian men, to assess the prevalence of symptoms and signs among men with Trichomonas vaginalis, and to analyse the risk factors for trichomoniasis.Design:A cross sectional study of 1004 men aged 15-54 years in a rural community in north west Tanzania.Methods:Participants were interviewed about sexual behaviour and symptoms of sexually transmitted diseases. First fraction urine samples and urethral swabs were collected and used to test for T vaginalis by wet preparation and culture, Neisseria gonorrhoeae by culture, Chlamydia trachomatis by ligase chain reaction and non-specific urethritis by Gram stain. Urine was also tested for the presence of leucocytes using a leucocyte esterase dipstick. Men were re-interviewed 2 weeks later to document new symptoms and signs of urethritis.Results:Complete laboratory results were available on 980 men. One in four men had laboratory evidence of urethritis. T vaginalis was found in 109 individuals (11%), gonorrhoea in eight (0.8%), and chlamydial infection in 15 (1.5%). Over 50% of men with urethritis were asymptomatic. The prevalence of signs and symptoms was similar among men with T vaginalis alone compared with men with other urethral infections. The sensitivity and specificity of the leucocyte esterase dipstick (LED) test for detecting T vaginalis were 80% and 48% respectively in symptomatic men and 60% and 68% in asymptomatic men. Factors associated with trichomoniasis included religion, type of employment, and marital status.Conclusions:A high prevalence of urethritis was found in men in this community based study. More than half of the urethral infections detected were asymptomatic. The most prevalent pathogen was T vaginalis. Studies are needed on the prevalence of trichomoniasis in men presenting to health services with complaints suggestive of urethritis since treatment for T vaginalis is not included in the syndromic management of urethritis in most countries. The performance of the LED test as a screening test for trichomoniasis was unsatisfactory in both symptomatic and asymptomatic men. Improved screening tests are urgently needed to identify urethral infections that are asymptomatic and which are not covered by current syndromic management algorithms.

Published
2000

49. The epidemiology of, and risk factors for, oro-genital and anal human papillomavirus infections among sexually active Nigerians in Ibadan : a mixed methods study

Author

Morhason-Bello, I. O., Watson-Jones, D., and Francis, S. C.

Abstract

Background: Human papillomavirus (HPV) is primarily transmitted by unprotected sexual behaviours, and persistence of this virus is associated with HPV-related cancers of the cervix, anus, vulvar, oral cavity and penis. Nigeria has one of the highest burdens of cervical cancer, but there is a paucity of data on other HPV-related cancers. Research objectives: To describe the epidemiology of HPV and the pattern of genital, oral and anal sexual intercourse and their association with the prevalence of genital, oral and anal HPV infections among adolescents and young adults and female sex workers (FSWs) (18-45 years) in Nigeria. Methods: First, a systematic review of reported oral and anal sex among heterosexual adolescents and adults in sub-Saharan Africa (SSA) was conducted. Second, a qualitative study that enrolled adolescent girls and young women in the community and in brothel-based FSW in Ibadan, Nigeria was conducted. The study used focus group discussions and in-depth interviews to collect data on definitions or meanings, attitudes and interpretations of different sexual behaviours. Third, a cross-sectional survey was conducted in Ibadan amongst girls and young women and FSWs to measure the prevalence and risk factors of oral, vulvar, cervical and anal HPV infections. Participants were interviewed, had a clinical examination and samples were collected for HPV genotyping. Blood samples were also collected for human immunodeficiency virus testing. Results: The systematic review showed that oral and anal sex are commonly practiced in SSA, particularly among adolescents, young adults and FSWs. In the qualitative study, most participants had heard of oral and anal sex; more adolescents and FSWs had heard of these practices than adults. Local terminology/slang terms for oral and anal sex were acceptable to adolescents and FSWs but adults in the community often disapproved of these terms for framing interview questions. The most common motivations for practicing oral and anal sex were protection of sexual relationships and financial benefits. Concerns about these practices included fear of acquiring diseases and physical injury. For the prevalence survey, 310 women, and 315 FSWs participated. Ever having practised oral sex was three times more frequently reported by FSWs than general population girls and women. Only one woman in the general population and eight FSWs had ever engaged in anal sex. The prevalences of any HPV genotypes were higher in FSWs than in general population 4 girls and women in the vulva (88% versus 69%), cervix (84% versus 60%), anal cavity (75% versus 57%) and oral cavity (24% versus 16%). The prevalence of HPV was significantly higher in adolescents and young adults than in adults in the cervix, vulvar and anal cavity in the two surveys. In the adjusted model, there were higher odds of cervical HPV infection among women with concomitant vulvar (Adjusted odds ratio (aOR)= 12.85, 95% CI, 5.70-28.99), oral (aOR= 4.37, 95% CI, 1.50-12.71) and anal (aOR=3.48, 95%CI, 1.74-6.96) HPV infection while women with concomitant cervical (aOR=22.19, 95 %CI 7.85-62.72) and anal (aOR=6.68, 95% CI 2.44-18.26) HPV infections had higher odds of vulvar HPV infection. The odds of having anal HPV infection was associated with history of concomitant cervical (aOR=4.10, 95% CI, 1.85- 9.11) and vulvar (aOR=5.47, 95% CI, 2.11-14.20) HPV infection. Only the history of concomitant cervical HPV (aOR=4.81, 95% CI, 1.58-14.62) was associated with a higher odd of oral HPV. Among the FSWs, history of concomitant vulvar HPV infection was associated with higher odds of cervical (aOR=16.60, 95% CI, 5.08-47.54) and anal (aOR=10.55, 95% CI, 3.67- 30.31 HPV infection, whereas history of concomitant cervical (aOR=6.48, 95% CI, 2.70-15.57) and anal (aOR=8.88, 95% CI, 3.66-23.28) HPV was associated with higher odds of vulvar HPV infections. The socio-demographic, behavioural and other biological factors that were associated with any HPV infections in specific anatomic sites are presented in the relevant chapters. Conclusion: Adolescents and adults, including FSWs in Ibadan, frequently engaged in different sexual behaviours, which might predispose them to sexually transmitted infections. HPV infection was found to be common among sexually active girls and women, with a higher prevalence among FSWs.

Published
2021
Full Text
View/download PDF

50. Epidemiology and natural history of human papillomavirus around the time of sexual debut

Author

Houlihan, C. F. and Watson-Jones, D.

Subjects
616.9
Abstract

Human papillomavirus (HPV) is a sexually transmitted virus associated with cervical cancer. The East African region has one of the highest incidences and mortality rates from cervical cancer but limited studies on HPV are available. Research aims were to describe: HPV genotypes, risk factors and rate of acquisition of prevalent and incident HPV in girls before and after reported first sex; rate and risk factors associated with HPV clearance, and to examine sexual behaviour reporting in face-to-face (FtF) interviews compared to Audio Computer-Assisted Self-Interviews (ACASI). A total of 503 girls aged 15 and 16 years in Mwanza, Tanzania, were enrolled and followed 3-monthly for 18 months with FtF-interviews and self-administered vaginal swabs. At enrolment, 474 girls reported no previous sex, and HPV was detected in 40/474(8.4%). During follow-up of girls who reported sex, new HPV incidence was 225/100 person-years(pys). Reporting sex in the past 3 months, and knowing the most recent sexual partner for a longer period before sex were associated with HPV acquisition. Median time from reported sexual debut to first HPV infection was 5 months, and median duration of infection 6 months. No factors were associated with HPV clearance. In girls who reported not having sex, HPV incidence was 29.4/100pys. ACASI was compared to FtF-interview in 203 girls at the 12-month visit. Although ACASI was feasible and acceptable, there was no increase in reporting of sex or other sexual behaviours, with the exception of kissing, compared to FtF-interviews. A very high incidence of HPV was seen in girls following sexual debut, and a higher than expected HPV prevalence and incidence were seen in girls who reported no previous sex. This emphasises the importance of HPV vaccination well before sexual debut. ACASI did not lead to increased reporting of vaginal sex and should be evaluated further in different settings.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results